Objective:To investigate the clinical effect of hepatic artery chemoembolization for liver cancer patients.Method:January 2010 to December 2012 in our hospital 70 patients with advanced hepatocellular carcinoma were selected as the research objects.According to the wishes of patients and their families,70 patients were divided into the observation group for 35 cases and the control group for 35 cases,the observation group was treated with hepatic arterial infusion chemotherapy embolism,the control group was treated with oral sorafenib treatment.Clinical effect in patients after 3 months of treatment were compared between the groups.Result:After 3 months of treatment,the total effective rate of observation group was 82.86%, significantly higher than the control group of 57.14%,the difference was statistically significant(P<0.05). The average survival period of observation group(29.42±5.39)months was longer than that in the control group(16.46±3.82)months,the difference was statistically significant(P<0.05).Conclusion:Transcatheter arterial chemoembolization treatment of hepatocellular carcinoma can effectively control the rapid development of the disease and prolong the lives of patients.%目的：探讨肝癌患者行肝动脉栓塞化疗的临床效果。方法：选取2010年1月-2012年12月期间在本院住院治疗的70例中晚期肝细胞肝癌患者为研究对象。根据患者及其家属的意愿，将70例患者分为观察组35例和对照组35例，观察组接受肝动脉介入化疗栓塞，对照组采用口服索拉非尼治疗。治疗3个月后比较两组患者的临床治疗效果。结果：观察组患者在治疗3个月后治疗的总有效率82.86%明显高于对照组患者的57.14%，比较差异有统计学意义（P<0.05）。观察组平均生存期（29.42±5.39）个月明显长于对照组的（16.46±3.82）个月，差异有统计学意义（P<0.05）。结论：经肝动脉化疗栓塞治疗肝细胞肝癌能有效控制疾病的快速发展，延长患者的生命。
展开▼
